Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907.10.1158/1055-9965.EPI-10-0437
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.10.1056/NEJMra1001683
   PubMed Web of Science ®Google Scholar
• Huang S, Ren X, Wang L, Zhang L, Wu X. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo. Cancer Prev Res (Phila). 2011;4:666–73.10.1158/1940-6207.CAPR-10-0235
   PubMed Web of Science ®Google Scholar
• Kelley SK, Ashkenazi A. Targeting death receptors in cancer with apo2 l/trail. Curr Opin Pharmacol. 2004;4:333–9.10.1016/j.coph.2004.02.006
   PubMed Web of Science ®Google Scholar
• Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with ifn-gamma to restore caspase-8 expression and overcome trail resistance in cancers with silencing of caspase-8. Oncogene. 2009;28:3097–110.10.1038/onc.2009.161
   PubMed Web of Science ®Google Scholar
• Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. 2010;464:1058–61.10.1038/nature08871
   PubMed Web of Science ®Google Scholar
• Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene. 2006;25:7333–5.10.1038/sj.onc.1209765
   PubMed Web of Science ®Google Scholar
• Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol. 2010;22:837–44.10.1016/j.ceb.2010.08.001
   PubMed Web of Science ®Google Scholar
• Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, et al. Randomized phase ii study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4442–51.10.1200/JCO.2011.37.2623
   PubMed Web of Science ®Google Scholar
• Carlisi D, D’Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, et al. Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol. 2011;226:1632–41.10.1002/jcp.22494
   PubMed Web of Science ®Google Scholar
• Fayyaz S, Yaylim I, Turan S, Kanwal S, Farooqi AA. Hepatocellular carcinoma: targeting of oncogenic signaling networks in TRAIL resistant cancer cells. Mol Biol Rep. 2014;41:6909–17.10.1007/s11033-014-3577-8
   PubMed Web of Science ®Google Scholar
• Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL. Synergism of cpt-11 and apo2 l/trail against two differentially sensitive human colon tumor xenografts. Oncology. 2008;74:188–97.10.1159/000151366
   PubMed Web of Science ®Google Scholar
• Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005;4:2026–36.10.1158/1535-7163.MCT-05-0262
   PubMed Web of Science ®Google Scholar
• Kim EY, Yu JS, Yang M, Kim AK. Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5. Mol Cells. 2013;35:32–40.10.1007/s10059-013-2175-2
   PubMed Web of Science ®Google Scholar
• Jiao P, Zhou YS, Yang JX, Zhao YL, Liu QQ, Yuan C, et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem. 2013;382:217–24.10.1007/s11010-013-1737-0
   PubMed Web of Science ®Google Scholar
• Zhang R, Xu LB, Yue XJ, Yu XH, Wang J, Liu C. Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil. Oncol Rep. 2013;29:967–74.
   PubMed Web of Science ®Google Scholar
• Xu SP, Sun GP, Shen YX, Wei W, Peng WR, Wang H. Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J Gastroenterol. 2007;13:250–6.10.3748/wjg.v13.i2.250
   PubMed Web of Science ®Google Scholar
• Witort E, Lulli M, Carloni V, Capaccioli S. Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells. J Chemother. 2013;25:292–7.10.1179/1973947813Y.0000000087
   PubMed Web of Science ®Google Scholar
• Chou TC, Martin N. CompuSyn software for drug combinations and for general dose-effect analysis, and user’s guide. Paramus, NJ: ComboSyn; 2007. http://www.combosyn.com
   Google Scholar
• Yang Y, Zhao S, Song J. Caspase-dependent apoptosis and -independent poly(adp-ribose) polymerase cleavage induced by transforming growth factor beta1. Int J Biochem Cell Biol. 2004;36:223–34.10.1016/S1357-2725(03)00215-2
   PubMed Web of Science ®Google Scholar
• Rodel F, Sprenger T, Kaina B, Liersch T, Rodel C, Fulda S, et al. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 2012;19:3679–88.10.2174/092986712801661040
   PubMed Web of Science ®Google Scholar
• Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008;14:6496–504.10.1158/1078-0432.CCR-08-0468
   PubMed Web of Science ®Google Scholar
• Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, et al. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011;12:229–38.10.4161/cbt.12.3.17033
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest. 2008;118:1979–90.10.1172/JCI34359
   PubMed Web of Science ®Google Scholar
• Charette N, De Saeger C, Horsmans Y, Leclercq I, Stärkel P. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis. 2013;4:e471.10.1038/cddis.2012.200
   Google Scholar
• Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27:6207–15.10.1038/onc.2008.298
   PubMed Web of Science ®Google Scholar
• Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, et al. Evaluation of pharmacodynamic biomarkers in a phase 1a trial of dulanermin (rhapo2 l/trail) in patients with advanced tumours. Br J Cancer. 2011;105:1830–8.10.1038/bjc.2011.456
   PubMed Web of Science ®Google Scholar
• Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene. 2012;31:4677–88.10.1038/onc.2011.614
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010;430:199–205.10.1042/BJ20100814
   PubMed Web of Science ®Google Scholar
• Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance apo-2 l-induced apoptosis of human acute leukemia cells. Blood. 2000;96:3900–6.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54.10.1038/nrc968
   PubMed Web of Science ®Google Scholar
• Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, et al. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today. 2011;41:175–82.10.1007/s00595-010-4390-1
   PubMed Web of Science ®Google Scholar
• Dai DJ, Lu CD, Lai RY, Guo JM, Meng H, Chen WS, et al. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroenterol. 2005;11:193–9.10.3748/wjg.v11.i2.193
   PubMed Web of Science ®Google Scholar
• Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007;67:11284–90.10.1158/0008-5472.CAN-07-2728
   PubMed Web of Science ®Google Scholar
• Zhao L, Sha YY, Zhao Q, Yao J, Zhu BB, Lu ZJ, et al. Enhanced 5-fluorouracil cytotoxicity in high cox-2 expressing hepatocellular carcinoma cells by wogonin via the pi3 k/akt pathway. Biochem Cell Biol. 2013;91:221–9.10.1139/bcb-2012-0077
   PubMed Web of Science ®Google Scholar